Nalbuphine

Dec 03, 2019

Lumosa Announces FDA Acceptance of IND Application for LT1001, an Extended-Release Analgesic Injection - Lumosa to Initiate the Bridging Study in the US

Apr 30, 2018

Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

Feb 28, 2018

Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions

Jan 29, 2018

Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal

Jan 16, 2018

Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals

Nov 06, 2017

Egalet Announces ARYMO ER Added to Large Payer Medicare Part D Formulary

Sep 08, 2017

Egalet Presented New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse

Aug 28, 2017

Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US

Jun 06, 2017

Egalet Announces ARYMO® ER Added to Large Payer Formulary